MagVenture announced FDA clearance for accelerated TMS (aTMS) protocols to treat major depressive disorder in adults. The clearance lets clinicians deliver from two up to ten sessions per day over a condensed schedule, allowing a full course to be completed in days rather than the traditional four to six weeks, while keeping the same safety and effectiveness profile as once-daily therapy.
The clearance applies to MagVenture's TMS Therapy system and covers both repetitive TMS (rTMS) and intermittent theta-burst stimulation (iTBS) protocols, with or without MRI-based neuronavigation, and requires no hardware or waveform changes. Standard targeting methods such as Beam F3 or the 5.5-cm rule remain clinically appropriate alternatives to advanced imaging.
Andre R. Brunoni of UT Southwestern Medical Center noted the flexibility lets clinicians tailor protocols to the individual patient rather than a fixed schedule. MagVenture, which operates in more than 60 countries with 35 years of experience, positioned the clearance as a way to compress the timeline for patients who cannot commit to weeks of daily visits.
For clinics, accelerated protocols mean higher throughput and the ability to serve patients who travel from a distance for treatment.
Source
Reporting based on coverage from MagVenture. This article is editorial summary intended for general information; it is not medical advice.
